EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Recent Progress in HDAC‐Based Dual‐Target Inhibitors for Colorectal Cancer

Jiaqi Yang iD, Xinyu Shi, Yang Xu, Qinghe Kong, Degang Kong, Yun Feng, Honglei Zhou iD

Drug Development Research · 2026-11 · 87 (7)

DOI: 10.1002/ddr.70403 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Development Research, online erschienen am 28.10.2026. Verfasst von Jiaqi Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, PR China. Hauptthemen laut MEDLINE: Histone Deacetylase Inhibitors, Colorectal Neoplasms, Antineoplastic Agents. Die Arbeit nennt 108 Literaturangaben. Gefördert von: Shandong Provincial Graduate Student Excellence and Quality Course Project, Clinical Research Special Project of Shandong University of Traditional Chinese Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal cancer (CRC) remains one of the leading causes of cancer‐related incidence and mortality worldwide, with accumulating evidence indicating that its tumorigenesis and progression are tightly linked to epigenetic dysregulation. Histone deacetylases (HDACs) are key epigenetic regulators involved in gene transcription, cell‐cycle regulation, and cancer progression, whereas the therapeutic benefits of conventional HDAC inhibitors are frequently compromised by limited selectivity and resistance development. Recently, dual‐target HDAC inhibitors (HDACis) have attracted considerable attention as an emerging paradigm in anticancer drug development. These multitarget strategies can simultaneously enhance synergistic antitumor efficacy and alleviate the compensatory resistance commonly associated with single‐target therapies via multi‐mechanistic interventions. Accordingly, the concurrent modulation of HDACs and additional therapeutic targets represents a viable therapeutic strategy for CRC. In this review, we systematically summarize the recent progress of dual‐target HDAC is in CRC treatment, with particular emphasis on their therapeutic potential and implications for future translational research and clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Histone Deacetylase InhibitorsColorectal NeoplasmsAntineoplastic AgentsHumansHistone DeacetylasesAnimalsEpigenesis, Genetic

Stichwörter der Autor:innen

colorectal cancerdual‐target HDAC inhibitorsstructure‐activity relationship

Substanzen

Histone Deacetylase InhibitorsHistone DeacetylasesAntineoplastic Agents

Autor:innen und Institutionen

  • College of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, PR China.

ORCID-Profile: Jiaqi Yang, Honglei Zhou

Förderung

  • Shandong Provincial Graduate Student Excellence and Quality Course Project
  • Clinical Research Special Project of Shandong University of Traditional Chinese Medicine

Zitieren

APA

Yang, J., Shi, X., Xu, Y., Kong, Q., Kong, D., Feng, Y., & Zhou, H. (2026). Recent Progress in HDAC‐Based Dual‐Target Inhibitors for Colorectal Cancer. Drug Development Research, 87(7). https://doi.org/10.1002/ddr.70403

Vancouver

Yang J, Shi X, Xu Y, Kong Q, Kong D, Feng Y, et al. Recent Progress in HDAC‐Based Dual‐Target Inhibitors for Colorectal Cancer. Drug Development Research. 2026;87(7). doi:10.1002/ddr.70403

BibTeX
@article{Yang2026,
  author = {Yang, Jiaqi and Shi, Xinyu and Xu, Yang and Kong, Qinghe and Kong, Degang and Feng, Yun and Zhou, Honglei},
  title = {Recent Progress in HDAC‐Based Dual‐Target Inhibitors for Colorectal Cancer},
  journal = {Drug Development Research},
  year = {2026},
  volume = {87},
  number = {7},
  doi = {10.1002/ddr.70403}
}
Kostenlos starten →